Could a common cholesterol drug help fight ovarian cancer?
NCT ID NCT04457089
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether adding simvastatin, a common cholesterol-lowering drug, to standard chemotherapy could slow cancer progression in women with recurrent platinum-sensitive ovarian cancer. 18 participants took simvastatin alongside carboplatin and liposomal doxorubicin. The main goal was to see if patients could stick with the treatment, and researchers also tracked cancer markers and survival time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-SENSITIVE OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink recurrent ovarian tumors
- New drug combo aims to outsmart recurrent ovarian cancer
- New drug duo aims to outperform chemo in ovarian cancer
- Could your own immune cells fight ovarian cancer? tiny trial aims to find out
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- New hope for ovarian cancer: Rina-S faces off against chemo in major trial